Forecast Of The Day: Boston Scientific’s Interventional Cardiology Revenues

-7.01%
Downside
68.49
Market
63.69
Trefis
BSX: Boston Scientific logo
BSX
Boston Scientific

What?

Trefis expects revenue from Boston Scientific’s (NYSE: BSX) Interventional Cardiology business – which sells products such as stents and catheters – to grow from around $2.3 billion in 2020 to about $2.7 billion in 2021 and over $2.8 billion in 2022.

Why?

Relevant Articles
  1. Should You Pick Boston Scientific Stock After A Solid Q4 And 13% Uptick This Year?
  2. What’s Next For Boston Scientific Stock After 5% Gains In A Week?
  3. Should You Pick MGM Resorts Over Boston Scientific Stock For Better Returns?
  4. Which Is A Better Buy – Boston Scientific Stock Or Abbott?
  5. What’s Next For Boston Scientific Stock After Outperforming During The 2022 Inflation Shock?
  6. New Product Launches To Aid Boston Scientific’s Q1

Although revenue dipped in 2020, due to the Covid-19 pandemic, we expect sales to rebound in 2021 as the number of elective surgeries and cardiac procedures increases post the lockdowns.

So What?

The re-opening of the economy and strong vaccination rates in the U.S. should bode well for Boston Scientific’s medical devices and consumables sales across its operating segments. We value BSX stock at $49 per share, about 15% ahead of the current market price.

See Our Complete Analysis For Boston Scientific

What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market since 2016

See all Trefis Price Estimates and Download Trefis Data here

What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams